Oct. 1, 2025
| Today’s news and insights for biopharma leaders
The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with significant layoffs and leadership upheaval this year.
|
A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.
|
Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA interference medicines past the blood-brain barrier.
|
Learn how softgels have helped sponsors across the industry improve the efficacy and stability of their therapeutics.
|
News roundup
George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new Novartis drug and two biotechs cut staff.
|
UPDATED
Against the backdrop of a government shutdown, the agency has a series of critical decisions ahead, among them verdicts on new therapies from Novo Nordisk and Biohaven.
|
|
Since 2022, Chinese companies account for 31% of the total global drug market. Learn how Western pharma companies can collaborate with China’s booming bioscience sector in this playbook.
|
|
From Our Library
Trendline
Supported by 10x Genomics
|
Survey Report
Custom content for Qiagen
|
Playbook
Custom content for Woven Health Collective
|
Playbook
Custom content for Lonza
|
| 
